An oral drug delivery licensing and product development company offering a range of proprietary formulation technologies for advanced therapeutics.
London, England
Joined March 2016
- Tweets53
- Following71
- Followers193
- Likes88
Pinned Tweet
We are delighted to announce that we've been awarded an @innovateuk grant to manufacture an oral antibody formulation using #Soteria in partnership with @ukCPI, @Pharmidex and @QuayPharma.
Read more here: intractpharma.com/2018/11/09…
An innovative capsule could take the gold-standard treatment for #CrohnsDisease – infliximab – out of hospital and into patients’ homes for the first time.
Find out about how this treatment can benefit Louise Barker from @ukCPI at: hubs.la/Q01bBVRk0
#WorldIBDDay
Scientist or Senior Scientist, Oral Protein Formulation job with Intract Pharma
jobs.newscientist.com/en-gb/…
Intract Pharma retweeted
What will the future of healthcare look like? How will technology impact the way you manage your health?
Chief Digital Officer at @sanofi shares his predictions 💡👨⚕️
euronews.com/next/2021/06/17…
April 22, 2021 | Featured
Intract Pharma and NIBEC Enter into an Agreement to Develop a Novel Oral Peptide Therapy for Treatment of Ulcerative Colitis.
intractpharma.com/2021/04/22…
April 01, 2021 | Featured
Intract Pharma Enters into Research Collaboration with Ferring Pharmaceuticals to Evaluate Oral delivery of Monoclonal Antibodies for Treatment of Chronic Gastrointestinal Diseases
August 20, 2020 | Featured
Intract Pharma Limited and Celltrion Group announce collaboration for development of oral Infliximab.
intractpharma.com/2020/08/20…
May 26, 2020 | Featured
Intract Pharma and N&S Pharmacy Investment announce partnership to develop orally-delivered GLP-1R agonist peptide therapeutic.
intractpharma.com/2020/05/26…
May 05, 2020 | Featured
Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics.
intractpharma.com/2020/05/05…
October 24, 2019 | Featured
Intract’s Soteria® and Phloral® Technologies Highlighted Among Revolutionary Approaches to Crack Oral Biologics Delivery Challenge
intractpharma.com/2019/10/24…
May 07, 2019 | Phloral
Carus Animal Health and Intract Pharma Enter Agreement to Develop Novel Drug Delivery Technology.
5th April 2019 London, UK and Tokyo, Japan: Intract Pharma Ltd and Neopharma Japan Co. Ltd, have announced entry into a collaboration to develop a novel therapeutic product for treatment of gastrointestinal diseases using Intract’s proprietary drug delivery technologies.
London, England, 27th March 2019.
Intract Pharma has announced the launch of a first product incorporating its colon targeting technology, Phloral®. The product - called Yaldigo®/Asacol 1600 has been created and is marketed by Tillotts Pharma AG, Switzerland. @tillotts_pharma
Intract Pharma retweeted
Great talk by Vipul Yadav from @intractpharma on their innovative #Phloral and #Soteria oral drug delivery technologies for the delivery of antibodies! @APS_PharmSci #PharmSci2019
Intract Pharma retweeted
Our partners @intractpharma are working on some exciting drug delivery technologies including enabling biologics, like monoclonal antibodies, to be given as tablets rather than injectables. intractpharma.com/fomulation…
Intract Pharma retweeted
Medication conundrums - @intractpharma are creating solutions to gut metabolism with innovative new oral drug delivery technology #veterinary #veterinarymedicine #vetinnovation #vetmed
intractpharma.com/
Intract has entered into an agreement with @carus_ah to develop new therapies for the Veterinary Market
Read More here:
intractpharma.com/2019/05/07…
#AnimalHealth #Veterinarian
We are proud to announce that we've entered into a collaboration with @Neopharma1 to develop a novel treatment for #Gastrointestinal diseases.
Read more here: intractpharma.com/2019/04/05…
Market launch of a first Phloral® coated product, read more here:
intractpharma.com/2019/03/27…
Intract Pharma retweeted
Our colleagues @intractpharma , a spin out company from the @School_Pharmacy, have successfully been awarded over £1.4million in funding from @innovateuk to develop a scalable manufacturing process for novel oral antibody products. Read more: bit.ly/2THQ0iL
